Cleveland Diagnostics Appoints Valerie Dixon as New Chief Financial Officer
Cleveland Diagnostics has appointed Valerie Dixon as its new CFO to support the scaled commercialization of its FDA-approved IsoPSA prostate cancer test. Dixon joins from Flagship Pioneering, where she served as a senior partner in financing services and previously worked at major financial institutions like Morgan Stanley and J.P. Morgan. This leadership change comes after Cleveland Diagnostics secured significant funding rounds totaling $89.4 million over the past two years to support its growth trajectory ahead of FDA approval for IsoPSA, which was granted in December 2025. The company is now focused on expanding commercial operations under new CEO Michael Iskra, a medtech veteran with experience at Bayer and Siemens.
Topics: CFO appointment commercialization strategy financial leadership